Recent News

• 11.02.2026 - Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
• 10.22.2026 - Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
• 10.15.2026 - Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
• 09.03.2026 - Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
• 08.03.2026 - Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
• 07.23.2026 - Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
• 05.18.2026 - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
• 05.07.2026 - Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
• 05.04.2026 - Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
• 04.30.2026 - Krystal Biotech to Present at Upcoming Scientific Conferences

Recent Filings

• 11.02.2026 - 8-K Current report
• 11.02.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - EX-99.1 EX-99.1
• 10.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.15.2026 - 8-K Current report
• 10.15.2026 - EX-99.1 EX-99.1
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.16.2026 - 4 Statement of changes in beneficial ownership of securities